Atypical Parkinsonism clinical trials at University of California Health
1 research study open to eligible people
Trial of Parkinson's And Zoledronic Acid
open to eligible people ages 60 years and up
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.
at UC Davis UC Irvine UCLA UCSF
Our lead scientists for Atypical Parkinsonism research studies include Caroline Tanner, MD.